Details

Autor(en) / Beteiligte

• PEETERS, P. A. M
• VAN LIER, J. J
• DE MERBEL, N. V
• OOSTERHUIS, B
• WIELING, J
• JONKMAN, J. H. G
• KLESSING, K
• BIBER, A

Titel

Pharmacokinetics of [14C]-labelled Losigamone and enantiomers after oral administration to healthy subjects

Ist Teil von

• European journal of drug metabolism and pharmacokinetics, 1998-01, Vol.23 (1), p.45-53

Ort / Verlag

Genève: Médecine et hygiène

Erscheinungsjahr

1998

Quelle

MEDLINE

Beschreibungen/Notizen

• Losigamone ((+/-)-(R*,S*)-5-(2-chlorophenylhydroxymethyl)-4-methoxy-2 (5H)-furanone; AO-33) is a new potential antiepileptic drug undergoing clinical development. In a crossover study, 200 mg [14C]-labelled Losigamone, as well as 100 mg of each of the unlabelled enantiomers, was administered to 5 healthy volunteers as an oral suspension. The objectives of the study were to determine the mode of elimination, the excretion balance, metabolic profile, the in vitro and in vivo binding to plasma proteins and the pharmacokinetics of both enantiomers in plasma. From the plasma concentration-time profiles of [14C]-radioactivity and unchanged Losigamone it can be concluded that the absorption of Losigamone occurs very rapidly and the plasma concentration of the parent compound versus total radioactivity was consistently about 40%. An overall recovery of total radioactivity of about 97% with 85% in urine and 12% in faeces was found. Protein binding was 50%. Losigamone was extensively metabolized, with only traces of unchanged drug found in urine. The predominant metabolic pathways are hydroxylation and conjugation. After administration of the pure enantiomers, significant differences in pharmacokinetics were observed. The mean oral clearance of the (-)-enantiomer was 1863 ml/min and of the (+)-enantiomer was 171 ml/min. There was no chiral inversion after administration of the enantiomers.